Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Gastrointestinal Over-The-Counter (OTC) Drugs Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The gastrointestinal over-the-counter (otc) drugs market has experienced robust expansion in recent years. Its value is expected to rise from $49.59 billion in 2025 to $53.74 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. The increase observed in previous periods is attributable to the widespread occurrence of digestive disorders, the ease of access to OTC medications, the growth of pharmacy retail networks, evolving urban lifestyles, and alterations in dietary patterns.
The market for gastrointestinal over-the-counter (OTC) drugs is projected to experience substantial expansion in the coming years. This market is anticipated to reach a value of $73.3 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this growth during the projection period include the increasing adoption of preventive digestive care, the expansion of e-commerce platforms, a rising demand for clean-label OTC products, an aging global population, and heightened awareness regarding digestive health. Key trends anticipated over the forecast timeframe encompass a surge in self-medication for various digestive ailments, an escalating need for rapidly effective OTC relief, a greater utilization of combined gastrointestinal formulations, the proliferation of online pharmacy sales, and an increasing inclination towards herbal and enzyme-derived products.
Get A Free Sample Report With In-Depth Market Insights:
Gastrointestinal Over-The-Counter (OTC) Drugs Market Industry Drivers: What’s Behind The Revenue Growth?
A growing incidence of digestive ailments is projected to boost the expansion of the gastrointestinal OTC drugs market in the foreseeable future. These conditions encompass various affections of the gastrointestinal tract, such as the stomach, intestines, and related organs. The surge in digestive issues primarily stems from increased consumption of processed, low-fiber diets, leading to compromised gut health and impaired digestion. Over-the-counter gastrointestinal medications alleviate symptoms of these disorders through mechanisms like stomach acid reduction, bowel movement regulation, and improvements in gut health. Such drugs offer quick and accessible relief for prevalent problems including acidity, constipation, and indigestion. For example, data from the IBD Registry Ltd., a non-profit organization based in the UK, revealed that in December 2023, the count of individuals suffering from inflammatory bowel disease (IBD) surpassed 5,300, indicating an increment of over 3,000 members since 2022. Consequently, the rising occurrence of digestive disorders is fueling the expansion of the gastrointestinal OTC drugs market.
Gastrointestinal Over-The-Counter (OTC) Drugs Market Segment Outlook: Which Categories Are Growing Fastest?
The gastrointestinal over-the-counter (otc) drugs market covered in this report is segmented –
1) By Product: Antacid, Laxatives, Anti-Diarrheal, Anti-Emetics, Other Products
2) By Formulation: Tablets, Capsules, Liquids, Other Formulations
3) By Indications: Heartburn, Diarrhoea, Constipation, Gastroesophageal Reflux Disease (GERD), Nausea, Vomiting, Motion Sickness, Other Indications
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Clinics, Home Healthcare, Other End-Users
Subsegments:
1) By Antacid: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Calcium Carbonate, Magnesium Hydroxide, Sodium Bicarbonate, Combination Antacids
2) By Laxatives: Bulk-Forming Laxatives, Stimulant Laxatives, Osmotic Laxatives, Stool Softeners, Lubricant Laxatives
3) By Anti-Diarrheal: Loperamide, Bismuth Subsalicylate, Probiotics, Electrolyte Solutions
4) By Anti-Emetics: Antihistamines, Bismuth Subsalicylate, Phosphorated Carbohydrate Solution, Ginger Supplements
5) By Other Products: Digestive Enzymes, Simethicone, Herbal Remedies, Activated Charcoal
#Gastrointestinal Over-The-Counter (OTC) Drugs Market Growth Trends: What’s Shaping The Future Outlook?
Key players within the gastrointestinal OTC drugs market are concentrating their efforts on creating sophisticated offerings, including over-the-counter proton pump inhibitors, designed to deliver efficient and sustained alleviation from conditions related to excess acid. These over-the-counter (OTC) proton pump inhibitors (PPIs) represent a category of non-prescription drugs formulated to diminish stomach acid secretion, frequently utilized for managing ailments like recurring heartburn, acid reflux (GERD), and gastric ulcers. An illustrative development occurred in March 2025 when Eisai Co., Ltd., a pharmaceutical firm based in Japan, secured regulatory approval in Japan for the transition of its product, Pariet S (rabeprazole sodium 10 mg), from prescription (RX) to over-the-counter (OTC) availability. This landmark decision established it as Japan’s inaugural OTC PPI to feature the identical active ingredient and dosage as its prescription counterpart. Pariet S addresses stomach pain, heartburn, and bloating, providing 24-hour relief through a convenient once-daily, easy-to-swallow tablet. Its introduction is intended to meet the increasing demand for potent treatments for gastric acid-related issues, driven by evolving lifestyle patterns and demographic shifts.
Gastrointestinal Over-The-Counter (OTC) Drugs Market Leading Companies And Competitive Benchmarking
Major companies operating in the gastrointestinal over-the-counter (otc) drugs market are Pfizer Inc., Procter & Gamble Co., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Reckitt Benckiser Group plc, Boehringer Ingelheim GmbH, Haleon plc, Sandoz AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Dr. Reddy’s Laboratories Ltd.
View The Full Gastrointestinal Over-The-Counter (OTC) Drugs Market Report:
Gastrointestinal Over-The-Counter (OTC) Drugs Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the gastrointestinal over-the-counter (OTC) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal over-the-counter (otc) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model